GSC
FATE icon

Ground Swell Capital’s Fate Therapeutics FATE Stock Holding History

Ground Swell Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$3K Buy
627
+527
+527% +$3.05K 0.01% 1722
2014
Q2 		$1K Buy
+100
New +$704 ﹤0.01% 1710

Other funds holding FATE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ground Swell Capital's FATE Position: Q3 2014 in Review

Ground Swell Capital increased its Fate Therapeutics (FATE) stake by 527% in Q3 2014, buying an estimated $3.05K and bringing the position to 627 shares worth $3K. The position accounts for 0.01% of the portfolio, ranked #1722.

Ground Swell Capital first reported a position in FATE in Q2 2014 and has held it in 2 quarters since. 22 funds tracked by Wall St. Rank hold FATE as of Q3 2014.

  • Ground Swell Capital held 627 shares of Fate Therapeutics worth $3K as of Q3 2014.
  • Ground Swell Capital bought 527 Fate Therapeutics shares in Q3 2014, an estimated $3.05K.
  • Fate Therapeutics made up 0.01% of Ground Swell Capital's portfolio in Q3 2014, its #1722 holding.
  • Ground Swell Capital first reported a position in Fate Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 22 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.